SelectQuote faces a DOJ investigation and investor lawsuit over alleged deceptive Medicare Advantage sales practices, triggering a sharp stock decline and regulatory scrutiny.
SelectQuote faces a securities class-action lawsuit following DOJ intervention over alleged deceptive Medicare Advantage sales, impacting investor confidence and regulatory compliance in the insurance market.
The federal government starts a 6-year AI-assisted prior authorization pilot in Washington and five other states to improve Medicare coverage decisions for costly procedures.
Jack County Hospital District adopts FY 2025-2026 budget with focus on capital needs, rural ambulance grants, and managing shifts between Medicare Advantage and traditional Medicare claims.
Smart Medigap Plans broadens Medicare supplement offerings in Texas, enhancing coverage options for Medicare beneficiaries including prescription drug and supplemental insurance.
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
Study shows value-based payment models with two-sided risk improve clinical quality outcomes for Medicare Advantage beneficiaries compared to fee-for-service.
The Trump administration's Medicare pilot introduces AI-driven prior authorization to reduce waste and control costs, raising regulatory and patient care concerns.
Recent legislative changes to Medicare’s drug price negotiation program expand orphan drug exclusions, delaying price negotiation for expensive specialty drugs and increasing costs for Medicare beneficiaries.
Medicare Part D sees near-universal prior authorization and rising out-of-pocket costs for GLP-1 drugs in 2025, reflecting insurer adjustments to new cost and regulatory pressures.
